| scholarly article | Q13442814 |
| P50 | author | Federico Pea | Q38544304 |
| Francesco Cristini | Q104757072 | ||
| Pierluigi Viale | Q113862183 | ||
| Mario Furlanut | Q115867398 | ||
| Federica Pavan | Q115867399 | ||
| P2093 | author name string | Massimo Crapis | |
| Camilla Negri | |||
| P2860 | cites work | Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia | Q22241905 |
| Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008 | Q24644984 | ||
| Prediction of creatinine clearance from serum creatinine | Q29615603 | ||
| Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study | Q33982863 | ||
| Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia | Q35879117 | ||
| Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability | Q36263480 | ||
| The pharmacokinetic and pharmacodynamic properties of vancomycin | Q36328971 | ||
| Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia | Q36428418 | ||
| Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity | Q36538707 | ||
| Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections | Q36777850 | ||
| Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin | Q36870858 | ||
| Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? | Q37211603 | ||
| Are glycopeptides still appropriate and convenient for empiric use? | Q37333194 | ||
| In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis | Q39559251 | ||
| Clinical pharmacokinetics of vancomycin | Q39743278 | ||
| TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients | Q40621864 | ||
| Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period | Q41066970 | ||
| Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy | Q43905496 | ||
| Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus | Q44755051 | ||
| Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy | Q45107382 | ||
| Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections | Q45127594 | ||
| Assessment of renal function in recently admitted critically ill patients with normal serum creatinine | Q45258125 | ||
| High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity | Q45302930 | ||
| Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage | Q46541443 | ||
| Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule. | Q46616448 | ||
| Vancomycin minimum inhibitory concentration as a predictor of mortality in methicillin-resistant Staphylococcus aureus bacteremia: a second look | Q46639389 | ||
| Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides | Q46691587 | ||
| Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin? | Q46728126 | ||
| Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q46826194 | ||
| Monitoring of vancomycin serum levels for the treatment of staphylococcal infections | Q46929797 | ||
| Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia | Q46933141 | ||
| Replacement of 24-h creatinine clearance by 2-h creatinine clearance in intensive care unit patients: a single-center study. | Q51911200 | ||
| Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus | Q80363319 | ||
| Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence | Q80363323 | ||
| Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05 | Q80595494 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| pharmacodynamics | Q725307 | ||
| vancomycin | Q424027 | ||
| P304 | page(s) | 1863-1867 | |
| P577 | publication date | 2009-02-17 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients | |
| P478 | volume | 53 |
| Q40104555 | A specially tailored vancomycin continuous infusion regimen for renally impaired critically ill patients |
| Q49142591 | A survey of beta-lactam antibiotics and vancomycin dosing strategies in intensive care units and general wards in Belgian hospitals |
| Q41103109 | Application of Intrawound Vancomycin Powder during Spine Surgery in a Patient with Dialysis-Dependent Renal Failure |
| Q84629245 | Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock |
| Q37650115 | Augmented renal clearance: implications for antibacterial dosing in the critically ill. |
| Q37516599 | Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter? |
| Q94563599 | Calculated initial parenteral treatment of bacterial infections: Pharmacokinetics and pharmacodynamics |
| Q42878250 | Clearance of vancomycin during continuous infusion in Intensive Care Unit patients: correlation with measured and estimated creatinine clearance and serum cystatin C |
| Q41736250 | Colistin and anti-Gram-positive bacterial agents against Acinetobacter baumannii |
| Q37867260 | Continuing education: alternative approaches to optimizing antimicrobial pharmacodynamics in critically ill patients |
| Q34777837 | Decreasing the time to achieve therapeutic vancomycin concentrations in critically ill patients: developing and testing of a dosing nomogram |
| Q51047130 | Design and prospective validation of a dosing instrument for continuous infusion of vancomycin: a within-population approach. |
| Q39048274 | Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients |
| Q42147280 | Failure of Vancomycin Continuous Infusion against Experimental Endocarditis Due to Vancomycin-Intermediate Staphylococcus aureus |
| Q38569678 | How to use vancomycin optimally in neonates: remaining questions |
| Q40936660 | In vivo activity of vancomycin combined with colistin against multidrug-resistant strains of Acinetobacter baumannii in a Galleria mellonella model |
| Q34274190 | Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions |
| Q53070940 | Individualising Therapy to Minimize Bacterial Multidrug Resistance. |
| Q42689710 | Influence of Mechanical Ventilation on the Pharmacokinetics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients |
| Q38000242 | Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis. |
| Q37700552 | Management of antibiotic resistance in the intensive care unit setting |
| Q83390539 | Management of antimicrobial use in the intensive care unit |
| Q37120168 | New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients |
| Q35862844 | Optimization of time to initial vancomycin target trough improves clinical outcomes |
| Q28069334 | Optimizing the Clinical Use of Vancomycin |
| Q48197188 | Pharmacokinetic/pharmacodynamic parameters for treatment optimization of infection due to antibiotic resistant bacteria: a summary for practical purposes in children and adults. |
| Q34309445 | Potent Synergy and Sustained Bactericidal Activity of a Vancomycin-Colistin Combination versus Multidrug-Resistant Strains of Acinetobacter baumannii |
| Q42772417 | Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model |
| Q37698194 | Recent changes in vancomycin use in renal failure |
| Q39386583 | Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients |
| Q26746932 | Review of vancomycin-induced renal toxicity: an update |
| Q33751736 | Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study |
| Q52670469 | Target-Controlled Continuous Infusion for Antibiotic Dosing: Proof-of-Principle in an In-silico Vancomycin Trial in Intensive Care Unit Patients. |
| Q38417173 | The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion |
| Q35640430 | Therapeutic drug monitoring of antimicrobials |
| Q48089081 | Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice |
| Q37892556 | Vancomycin dosing and monitoring 2 years after the guidelines |
| Q34026240 | Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation |
| Q35004943 | Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens |
| Q37845424 | Vancomycin dosing in patients on intermittent hemodialysis |
| Q38818376 | Vancomycin dosing nomograms targeting high serum trough levels in different populations: pros and cons |
| Q38258649 | Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections. |